PASSANTINO, SILVIA
 Distribuzione geografica
Continente #
NA - Nord America 423
EU - Europa 277
AS - Asia 105
AF - Africa 2
SA - Sud America 2
Totale 809
Nazione #
US - Stati Uniti d'America 421
IE - Irlanda 73
PL - Polonia 59
IT - Italia 58
SE - Svezia 56
HK - Hong Kong 44
CN - Cina 23
RU - Federazione Russa 16
SG - Singapore 16
JO - Giordania 13
CH - Svizzera 7
VN - Vietnam 5
IN - India 3
CA - Canada 2
GB - Regno Unito 2
LY - Libia 2
PY - Paraguay 2
DE - Germania 1
FI - Finlandia 1
FR - Francia 1
KR - Corea 1
PT - Portogallo 1
RO - Romania 1
UA - Ucraina 1
Totale 809
Città #
Dublin 73
Warsaw 56
Fairfield 55
Ashburn 42
Chandler 39
Hong Kong 32
Seattle 28
Wilmington 24
Lawrence 19
Altamura 18
New York 18
Woodbridge 18
Cambridge 17
Florence 17
Houston 17
Buffalo 12
Princeton 12
Shanghai 11
Boston 10
Moscow 10
Beijing 9
Ann Arbor 8
Singapore 8
Bern 7
Kent 6
Dong Ket 4
Hillsboro 4
San Diego 4
Andover 3
Boardman 3
Medford 3
Naples 3
Falls Church 2
Prato 2
Pune 2
Roncade 2
Salerno 2
Siena 2
St. Catharines 2
Washington 2
West Jordan 2
Bruino 1
Cetraro 1
Chennai 1
Clifton 1
Duncan 1
Frankfurt am Main 1
Genova 1
Hanoi 1
Kilburn 1
Lappeenranta 1
London 1
Mem Martins 1
Milan 1
Monte San Savino 1
Norwalk 1
Padova 1
Seoul 1
Sestri Levante 1
Timișoara 1
Totale 627
Nome #
Sex-related differences in exercise performance and outcome of patients with hypertrophic cardiomyopathy 109
Long-term Outcomes of Pediatric-Onset Hypertrophic Cardiomyopathy and Age-Specific Risk Factors for Lethal Arrhythmic Events 109
Timing of invasive septal reduction therapies and outcome of patients with obstructive hypertrophic cardiomyopathy 70
Impact of cardiovascular involvement on the clinical course of paediatric mitochondrial disorders 69
Cardiomyopathies in children – inherited heart muscle disease: Overview of hypertrophic, dilated, restrictive and non-compaction phenotypes 56
P2316Outcome of septal reduction therapies for obstructive hypertrophic cardiomyopathy in a high-flow referral centre with moderate volume procedural programmes 52
Efficacy and safety of dysopiramide in patients with obstructive hypertrophic cardiomyopathy 47
Genetic basis of pediatric sarcomeric hypertrophic cardiomyopathy: impact on long term outcome 41
Predictive value of classic sudden death risk factors in pediatric-onset hypertrophic cardiomyopathy 39
Hidden familial cardiomyopathies in children: Role of genetic testing 38
Clinical profile and outcome of cardiomyopathies in infants and children seen at a tertiary centre 33
Clinical presentation and long-term outcomes of infantile hypertrophic cardiomyopathy: a European multicentre study 31
Indicazioni all’esecuzione del test genetico nella diagnosi delle cardiomiopatie ad esordio pediatrico: percorso clinico della Società Italiana di Cardiologia Pediatrica 28
Clinical pathway for cardiomyopathies: A genetic testing strategy proposed by ANMCO in Tuscany 24
Clinical Exome Sequencing Revealed a De Novo FLNC Mutation in a Child with Restrictive Cardiomyopathy 23
The role of the electrocardiographic phenotype in risk stratification for sudden cardiac death in childhood hypertrophic cardiomyopathy 23
Genetic Testing and Counselling in Hypertrophic Cardiomyopathy: Frequently Asked Questions 21
Safety and efficacy of ranolazine in hypertrophic cardiomyopathy: Real-world experience in a National Referral Center 16
Real-World Use and Predictors of Response to Disopyramide in Patients with Obstructive Hypertrophic Cardiomyopathy 3
Totale 832
Categoria #
all - tutte 3.760
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.760


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020117 1 0 0 5 9 13 22 20 18 9 12 8
2020/2021120 9 13 10 15 5 6 4 11 10 26 5 6
2021/202271 0 4 4 2 2 2 2 5 11 2 16 21
2022/2023297 21 64 17 1 20 54 39 21 37 4 10 9
2023/2024186 2 16 22 3 7 41 9 47 2 15 12 10
2024/202522 22 0 0 0 0 0 0 0 0 0 0 0
Totale 832